India's Lupin launches generic TriCor in U.S.
MUMBAI Nov 20 (Reuters) - Indian drugmaker Lupin Ltd said on Tuesday it launched a generic version of Abbott Laboratories' cholesterol lowering drug TriCor in the United States.
Lupin got its generic fenofibrate drug approved by the U.S. Food and Drug Administration last December.
Tricor tablets have annual sales of $1.26 billion in the United States, Lupin said in a statement.
Valued $4.46 billion, shares in Lupin closed 1.11 percent up at 568.15 rupees on Tuesday, when the Mumbai stock market was almost flat.
- Flights delayed as air pollution hits record in Shanghai
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- French launch Central African Republic mission but deaths mount
- Supreme Court to decide on patent protections for software